Fat absorption and gastroenteric pH profile in postsurgical pancreatic insufficiency: role of the association of H2-receptor antagonists with pancreatic enzymes.
The complete control of steatorrhea in post-surgical exocrine pancreatic insufficiency is difficult. The aim of this study was to evaluate the effect of the association of ranitidine with pancrelipase om fecal fat excretion in patients who had undergone a pancreatoduodenectomy with suppression of the exocrine pancreatic secretion by Neoprene injection. Ten patients were studied 1 year after surgery. Steatorrhea was measured as an integrated test of 3-day stools, while patients were kept on a diet of 100 g lipid/day, with their usual enzyme supplementation therapy (16,050 USP units of lipase/meal). A basal 24-h gastroenteric pH profile was also obtained. In the following month, patients had ranitidine (150 mg twice a day) in addition to pancrelipase. Then steatorrhea and gastroenteric pH were reassessed. Mean fecal fat was 26.9 (SD 13.7) g/day without ranitidine and 30.5 (SD 13.9) g/day during combined treatment. Body weight and nutritional parameters did not show any significant variation after ranitidine administration. Even in the absence of ranitidine, postprandial gastroenteric pH values were always > 4; the H2-receptor antagonist only reduced fasting gastric acidity. In conclusion, the gastroenteric pH and fecal fat determinations showed that ranitidine is not useful in patients with total postsurgical exocrine pancreatic insufficiency.
Braga
M
M
Department of Surgery, Scientific Institute San Raffaele, Milan, Italy.
Zerbi
A
A
Malesci
A
A
Dal Cin
S
S
Valentini
A
A
Tacconi
M
M
Erenbourg
L
L
Paganelli
M
M
Di Carlo
V
V
D000328:Adult; D000368:Aged; D004041:Dietary Fats / Q000378:metabolism*; D004063:Digestion / Q000502:physiology; D004064:Digestive System / Q000503:physiopathology*; D010188:Exocrine Pancreatic Insufficiency / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D007408:Intestinal Absorption / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009752:Nutritional Status; D010179:Pancreas / Q000187:drug effects* / Q000201:enzymology; D016577:Pancreaticoduodenectomy; D011183:Postoperative Complications
D004041:Dietary Fats; D006635:Histamine H2 Antagonists